Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11
Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11
Regeneron 和 賽諾菲安萬特的Dupixent獲得歐盟批准，用於1到11歲患兒的嗜酸性食道炎，爲他們帶來新希望
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year
批准基於第3期數據，顯示相比安慕希的安慕希，12到16週歲的兒童更多使用Dupixent實現組織學疾病緩解，這種緩解持續了一年
Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial
Dupixent是歐盟首個適用於治療這些年輕患者的藥物，他們在生長至關重要的關鍵階段持續難以進食
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間